Bharat Immunologicals & Biologicals Corporation Ltd-$
Bharat Immunologicals & Biologicals Corporation Ltd-$ (BIBCL) last reported results for the quarter ended Sep 2023, with sales of ₹0 crore and net profit of ₹-4.92 crore. The stock last traded at ₹7.4, a market capitalisation of ₹31.9 crore. Over the past 52 weeks the stock has ranged between ₹7.12 and ₹22.6. Figures are as of 6 Oct 2026 and are not real time.
Bharat Immunologicals & Biologicals Corporation Ltd-$ share price and key metrics
- Current price
- ₹7.4
- Market cap
- ₹31.9 cr
- Book value
- ₹18.2
- ROE
- -17.7%
- ROCE
- -9.27%
- Dividend yield
- 0.00%
- 52w high / low
- 22.6/7.12
Metrics as of 6 Oct 2026. Not real time.
Track Bharat Immunologicals & Biologicals Corporation Ltd-$
Cruxal reads every Bharat Immunologicals & Biologicals Corporation Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Bharat Immunologicals & Biologicals Corporation Ltd-$ growth and returns
- 10 Years
- -13%
- 5 Years
- 5%
- 3 Years
- -13%
- TTM
- -90%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -31%
- TTM
- -42%
- 10 Years
- -8%
- 5 Years
- -33%
- 3 Years
- -32%
- 1 Year
- -64%
- 10 Years
- -12%
- 5 Years
- -24%
- 3 Years
- -23%
- Last Year
- -18%
Bharat Immunologicals & Biologicals Corporation Ltd-$ quarterly results
In the quarter ended Sep 2023, sales were ₹0 cr, down 100.0% from ₹26.48 cr a year earlier. Net profit was ₹-4.92 cr, down 59.7% year on year.
| ₹ crore | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17.43 | 22.04 | 10.48 | 26.48 | 0 | 7.65 | 0 | 0 |
| Expenses | 16.41 | 25.71 | 15.31 | 28.98 | 4.72 | 11.67 | 4.31 | 4.68 |
| Operating profit | 1.02 | -3.67 | -4.83 | -2.5 | -4.72 | -4.02 | -4.31 | -4.68 |
| OPM % | 5.85% | -16.65% | -46.09% | -9.44% | — | -52.55% | — | — |
| Other income | 0.12 | 0.59 | 0.14 | 0.32 | 0.1 | 0.49 | 0.1 | 0.16 |
| Interest | 1.54 | 1.68 | 1.58 | 1.74 | 1.67 | 2.06 | 1.72 | 2.09 |
| Depreciation | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.09 | 0.03 | 0.03 |
| Profit before tax | -0.44 | -4.81 | -6.31 | -3.96 | -6.33 | -5.68 | -5.96 | -6.64 |
| Tax % | -25.00% | -11.02% | -20.76% | -22.22% | -26.07% | -31.69% | -23.15% | -26.05% |
| Net profit | -0.33 | -4.28 | -5 | -3.08 | -4.68 | -3.88 | -4.59 | -4.92 |
| EPS (₹) | -0.08 | -0.99 | -1.16 | -0.71 | -1.08 | -0.90 | -1.06 | -1.14 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bharat Immunologicals & Biologicals Corporation Ltd-$ annual results
| ₹ crore | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 |
| Operating profit | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
| OPM % | 6% | 2.3% | -3.1% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
| Net profit | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| EPS (₹) | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
TTM is the trailing twelve months to the most recent quarter.
Bharat Immunologicals & Biologicals Corporation Ltd-$ balance sheet
| ₹ crore | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
| Borrowings | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 |
| Other liabilities | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 |
| Total liabilities | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| Fixed assets | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 |
| Total assets | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
As reported by the company. Total assets equal total liabilities by construction.
Bharat Immunologicals & Biologicals Corporation Ltd-$ cash flow
| ₹ crore | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| Cash from investing | 0 | 0 | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 |
| Cash from financing | -6 | -1 | -2 | -3 | -1 | 31 | -34 | -12 | 45 | -15 |
| Net cash flow | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
| Free cash flow | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| CFO / operating profit | -99% | 229% | 239% | -132% | -32% | 344% | -328% | -56% | 847% | -59% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Bharat Immunologicals & Biologicals Corporation Ltd-$ operating ratios
| Per year | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
| Debtor days | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
| Inventory days | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
| Days payable | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
| Cash conversion cycle | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
| Working capital days | 21 | 20 | 28 | -19 | 59 | 10 | -108 | -174 | -227 | -549 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Bharat Immunologicals & Biologicals Corporation Ltd-$ shareholding pattern
Promoters held 59.25% at Mar 2024, broadly unchanged since Mar 2023.
| % held | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% |
| Public | 40.75% | 40.75% | 40.75% | 40.74% | 40.74% | 40.75% | 40.75% | 40.74% |
| No. of shareholders | 35,695 | 35,442 | 36,242 | 35,550 | 34,818 | 34,201 | 34,910 | 35,313 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Bharat Immunologicals & Biologicals Corporation Ltd-$ corporate filings
- Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) Announces Government-Approved ClosureCompany Updatehigh impact
Cruxal's analysis: Bharat Immunologicals & Biologicals Corporation Limited has formally disclosed that the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.